Mindie Nguyen, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 6
Offices
6 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G79013 · Current
Licensed to practise in California · since 1994 · expires 2027-10-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$56,770
Medicare paid this office $56,770 for 221 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 167 | $35,242 | $103 |
| Long return visit (40+ min) | 43 | $9,444 | $160 |
| New patient visit (60+ min) | 20 | $3,375 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,448 | $106 |
| New patient visit (45+ min) | 12 | $1,511 | $126 |
See all 7 services
| Return visit (30+ min) | 167 | $35,242 | $103 |
| Long return visit (40+ min) | 43 | $9,444 | $160 |
| New patient visit (60+ min) | 20 | $3,375 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,448 | $106 |
| New patient visit (45+ min) | 12 | $1,511 | $126 |
| Short return visit (20+ min) | 13 | $818 | $55 |
| Measurement of liver stiffness | 26 | $217 | $8 |
Who their Medicare patients are
221 Original Medicare patients in 2024. Average age 73 · Under 65 6% · 85 and older 8% · Women 55% · Also on Medicaid 37% · Health risk score 1.96. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 73% · Diabetes 45% · Chronic kidney disease 32% · Coronary heart disease 22% · Heart failure 20% · Atrial fibrillation 20% · Depression 18% · COPD 16% · Cancer 14% · Dementia 9% · Stroke 5%.
The office billed $270,109, Medicare allowed $78,266 and paid $56,770; for 529 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 221 | 529 | 73 | 1.96 | $270,109 | $56,770 |
| 2023 | 182 | 329 | 72 | 2.01 | $165,742 | $30,451 |
| 2022 | 216 | 545 | 71 | 2.48 | $282,031 | $48,743 |
| 2021 | 190 | 658 | 71 | 2.26 | $321,819 | $61,241 |
| 2020 | 188 | 541 | 69 | 2.41 | $215,048 | $36,808 |
| 2019 | 170 | 333 | 70 | 2.41 | $100,112 | $25,020 |
| 2018 | 147 | 282 | 69 | 2.94 | $71,332 | $18,532 |
| 2017 | 204 | 495 | 69 | 3.17 | $105,743 | $32,291 |
| 2016 | 198 | 468 | 68 | 2.64 | $111,791 | $33,064 |
| 2015 | 220 | 503 | 67 | 2.61 | $125,350 | $37,193 |
| 2014 | 215 | 655 | 68 | 2.68 | $193,124 | $58,414 |
| 2013 | 227 | 631 | 67 | 2.45 | $196,713 | $58,638 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 106 | $14,582 | $97 |
| Return visit (30+ min) | 26 | $4,792 | $84 |
| Long return visit (40+ min) | 20 | $3,285 | $149 |
| New patient visit (60+ min) | 14 | $2,215 | $158 |
| New patient visit (45+ min) | 13 | $1,701 | $131 |
| Short return visit (20+ min) | 17 | $987 | $55 |
| Telehealth originating site facility fee | 16 | $428 | $20 |
2022: 10 services
| Return visit (30+ min) | 136 | $25,021 | $101 |
| Return visit (30+ min) | 31 | $5,920 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,658 | $85 |
| Long return visit (40+ min) | 19 | $3,223 | $146 |
| Long return visit (40+ min) | 13 | $2,454 | $129 |
| New patient visit (60+ min) | 13 | $2,357 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,475 | $123 |
| Telehealth originating site facility fee | 40 | $1,212 | $21 |
| Short return visit (20+ min) | 13 | $826 | $59 |
| Measurement of liver stiffness | 13 | $126 | $10 |
2021: 7 services
| Return visit (30+ min) | 132 | $28,041 | $101 |
| Long return visit (40+ min) | 37 | $9,451 | $166 |
| Return visit (30+ min) | 32 | $8,803 | $91 |
| Long return visit (40+ min) | 18 | $3,670 | $131 |
| New patient visit (60+ min) | 13 | $2,342 | $180 |
| Telehealth originating site facility fee | 51 | $1,980 | $21 |
| Measurement of liver stiffness | 13 | $123 | $9 |
2020: 8 services
| Return visit (30+ min) | 124 | $15,588 | $74 |
| Return visit (30+ min) | 35 | $7,407 | $67 |
| New patient visit (45+ min) | 16 | $1,894 | $118 |
| Long return visit (40+ min) | 16 | $1,799 | $112 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,710 | $95 |
| Telehealth originating site facility fee | 52 | $1,601 | $22 |
| Short return visit (20+ min) | 26 | $1,213 | $45 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,052 | $75 |
2019: 4 services
| Return visit (30+ min) | 99 | $12,939 | $81 |
| Return visit (30+ min) | 39 | $6,370 | $68 |
| Short return visit (20+ min) | 41 | $2,205 | $48 |
| New patient visit (45+ min) | 16 | $1,850 | $116 |
2018: 4 services
| Return visit (30+ min) | 59 | $6,481 | $64 |
| Return visit (30+ min) | 45 | $5,445 | $84 |
| Short return visit (20+ min) | 33 | $2,001 | $56 |
| Short return visit (20+ min) | 44 | $1,643 | $36 |
2017: 5 services
| Return visit (30+ min) | 103 | $15,126 | $65 |
| Return visit (30+ min) | 35 | $4,985 | $84 |
| Short return visit (20+ min) | 61 | $3,222 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,008 | $65 |
| Short return visit (20+ min) | 25 | $1,751 | $56 |
2016: 5 services
| Return visit (30+ min) | 96 | $13,089 | $63 |
| Return visit (30+ min) | 53 | $9,518 | $89 |
| Short return visit (20+ min) | 44 | $2,370 | $44 |
| New patient visit (45+ min) | 13 | $1,655 | $127 |
| Short return visit (20+ min) | 20 | $1,237 | $52 |
2015: 6 services
| Return visit (30+ min) | 101 | $12,913 | $63 |
| Return visit (30+ min) | 65 | $10,605 | $91 |
| Short return visit (20+ min) | 44 | $2,138 | $43 |
| Short return visit (20+ min) | 28 | $2,074 | $61 |
| New patient visit (45+ min) | 17 | $1,618 | $95 |
| Long return visit (40+ min) | 12 | $1,192 | $99 |
2014: 8 services
| Return visit (30+ min) | 73 | $17,128 | $95 |
| Return visit (30+ min) | 91 | $12,344 | $65 |
| Long return visit (40+ min) | 52 | $9,721 | $93 |
| Long return visit (40+ min) | 27 | $5,975 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,713 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,821 | $166 |
| New patient visit (45+ min) | 14 | $1,482 | $106 |
| Short return visit (20+ min) | 13 | $591 | $45 |
2013: 7 services
| Long return visit (40+ min) | 73 | $12,134 | $89 |
| Return visit (30+ min) | 53 | $10,487 | $92 |
| Long return visit (40+ min) | 39 | $9,764 | $127 |
| Return visit (30+ min) | 92 | $9,484 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $6,424 | $90 |
| New patient visit (60+ min) | 31 | $4,226 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,642 | $176 |
Medicaid work
$5,728 in 2024
Medicaid paid $5,728 for 177 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 177 | $5,728 |
| 2024 | 177 | 1 | 26 | $5,728 |
| 2023 | 153 | 1 | 29 | $3,044 |
| 2022 | 237 | 2 | 25 | $6,919 |
| 2021 | 282 | 2 | 28 | $7,433 |
| 2020 | 247 | 2 | 26 | $4,906 |
| 2019 | 118 | 1 | 27 | $1,952 |
| 2018 | 102 | 1 | 26 | $2,226 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 153 | $3,044 |
2022
| Return visit (30+ min) | 224 | $6,713 |
| Telehealth originating site facility fee | 13 | $206 |
2021
| Return visit (30+ min) | 270 | $7,283 |
| Telehealth originating site facility fee | 12 | $150 |
2020
| Return visit (30+ min) | 222 | $4,184 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 25 | $722 |
2019
| Return visit (30+ min) | 118 | $1,952 |
2018
| Return visit (30+ min) | 102 | $2,226 |
Drugs they prescribed that Part D paid
$613,860
Pharmacies billed $613,860 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 888) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
637 generic and fewer than 11 brand-name prescriptions · $613,860 in drug cost · 57 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 174 | $257,710 | $1,481 |
| Xifaxan | 48 | $160,049 | $3,334 |
| Entecavir | 109 | $24,785 | $227 |
| Tacrolimus | 88 | $13,614 | $155 |
| Sirolimus | 26 | $9,478 | $365 |
See all 19 drugs
| Vemlidy | 174 | $257,710 | $1,481 |
| Xifaxan | 48 | $160,049 | $3,334 |
| Entecavir | 109 | $24,785 | $227 |
| Tacrolimus | 88 | $13,614 | $155 |
| Sirolimus | 26 | $9,478 | $365 |
| Mycophenolate Mofetil | 57 | $4,662 | $82 |
| Ursodiol | 11 | $2,542 | $231 |
| Cyclosporine Modified | 31 | $2,536 | $82 |
| Tenofovir Disoproxil | 32 | $1,350 | $42 |
| Azathioprine | 12 | $514 | $43 |
| Pantoprazole | 51 | $484 | $9 |
| Mycophenolic Acid | 13 | $349 | $27 |
| Fludrocortisone Acetate | 18 | $249 | $14 |
| Amlodipine Besylate | 44 | $201 | $5 |
| Lactulose | 12 | $100 | $8 |
| Spironolactone | 11 | $95 | $9 |
| Tamsulosin | 16 | $64 | $4 |
| Carvedilol | 13 | $44 | $3 |
| Metoprolol | 11 | $31 | $3 |
Year by year
| 2024 | 888 | 91 | 0% (0) | None | $613,860 |
| 2023 | 863 | 81 | 0% (0) | None | $474,577 |
| 2022 | 922 | 97 | 0% (0) | 29% | $493,437 |
| 2021 | 852 | 105 | 0% (0) | 32% | $502,987 |
| 2020 | 844 | 100 | 0% (0) | None | $563,705 |
| 2019 | 852 | 89 | 0% (0) | None | $386,691 |
| 2018 | 1,144 | 95 | None | 26% | $1,024,823 |
| 2017 | 1,345 | 114 | 0% (0) | 34% | $2,152,437 |
| 2016 | 1,480 | 122 | None | 35% | $2,923,722 |
| 2015 | 1,559 | 123 | 1% (22) | None | $2,662,273 |
| 2014 | 1,391 | 123 | 1% (15) | 45% | $3,281,095 |
| 2013 | 992 | 108 | 1% (13) | 50% | $667,176 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Vemlidy | 166 | $237,852 | $1,433 |
| Xifaxan | 49 | $167,080 | $3,410 |
| Entecavir | 86 | $23,027 | $268 |
| Tacrolimus | 93 | $13,181 | $142 |
| Sirolimus | 26 | $11,046 | $425 |
| Mycophenolic Acid | 12 | $3,330 | $277 |
| Ursodiol | 11 | $3,213 | $292 |
| Cyclosporine Modified | 30 | $3,080 | $103 |
| Mycophenolate Mofetil | 51 | $2,102 | $41 |
| Lactulose | 18 | $1,289 | $72 |
| Pantoprazole | 44 | $766 | $17 |
| Amlodipine Besylate | 44 | $669 | $15 |
| Tenofovir Disoproxil | 25 | $514 | $21 |
| Azathioprine | 11 | $491 | $45 |
| Fludrocortisone Acetate | 21 | $346 | $16 |
| Metoprolol | 15 | $91 | $6 |
| Furosemide | 12 | $81 | $7 |
2022: 20 drugs
| Xifaxan | 69 | $218,228 | $3,163 |
| Vemlidy | 146 | $195,206 | $1,337 |
| Entecavir | 105 | $27,134 | $258 |
| Sirolimus | 48 | $12,762 | $266 |
| Tacrolimus | 75 | $6,054 | $81 |
| Mycophenolic Acid | 13 | $3,607 | $277 |
| Ursodiol | 13 | $3,023 | $233 |
| Cyclosporine Modified | 27 | $2,735 | $101 |
| Mycophenolate Mofetil | 24 | $2,470 | $103 |
| Tenofovir Disoproxil | 31 | $1,572 | $51 |
| Lactulose | 23 | $1,333 | $58 |
| Pantoprazole | 41 | $780 | $19 |
| Fludrocortisone Acetate | 31 | $556 | $18 |
| Azathioprine | 12 | $449 | $37 |
| Gabapentin | 13 | $399 | $31 |
| Potassium Chloride | 13 | $397 | $31 |
| Amlodipine Besylate | 35 | $365 | $10 |
| Glipizide | 18 | $275 | $15 |
| Furosemide | 33 | $155 | $5 |
| Ciprofloxacin | 16 | $117 | $7 |
2021: 21 drugs
| Vemlidy | 162 | $205,775 | $1,270 |
| Xifaxan | 55 | $158,794 | $2,887 |
| Entecavir | 73 | $21,369 | $293 |
| Sirolimus | 45 | $16,238 | $361 |
| Ursodiol | 28 | $5,073 | $181 |
| Mycophenolic Acid | 12 | $3,779 | $315 |
| Tacrolimus | 32 | $2,846 | $89 |
| Cyclosporine Modified | 22 | $2,753 | $125 |
| Mycophenolate Mofetil | 34 | $2,633 | $77 |
| Tenofovir Disoproxil | 25 | $2,356 | $94 |
| Generlac | 11 | $1,149 | $104 |
| Azathioprine | 18 | $725 | $40 |
| Gabapentin | 12 | $706 | $59 |
| Pantoprazole | 36 | $678 | $19 |
| Lactulose | 16 | $507 | $32 |
| Amlodipine Besylate | 48 | $347 | $7 |
| Spironolactone | 13 | $219 | $17 |
| Omeprazole | 17 | $217 | $13 |
| Furosemide | 30 | $175 | $6 |
| Hydroxyzine | 11 | $89 | $8 |
| Atorvastatin | 12 | $40 | $3 |
2020: 19 drugs
| Vemlidy | 162 | $206,338 | $1,274 |
| Xifaxan | 51 | $144,517 | $2,834 |
| Entecavir | 92 | $32,212 | $350 |
| Baraclude | 14 | $19,791 | $1,414 |
| Viread | 12 | $15,894 | $1,325 |
| Sirolimus | 41 | $13,075 | $319 |
| Ursodiol | 24 | $8,923 | $372 |
| Tacrolimus | 39 | $6,252 | $160 |
| Cyclosporine Modified | 36 | $5,401 | $150 |
| Mycophenolate Mofetil | 52 | $3,681 | $71 |
| Tenofovir Disoproxil | 26 | $3,673 | $141 |
| Mycophenolic Acid | 12 | $3,057 | $255 |
| Azathioprine | 12 | $403 | $34 |
| Pantoprazole | 32 | $328 | $10 |
| Spironolactone | 18 | $251 | $14 |
| Omeprazole | 18 | $187 | $10 |
| Potassium Chloride | 11 | $180 | $16 |
| Furosemide | 32 | $169 | $5 |
| Amlodipine Besylate | 31 | $104 | $3 |
2019: 21 drugs
| Xifaxan | 54 | $128,905 | $2,387 |
| Vemlidy | 84 | $97,200 | $1,157 |
| Entecavir | 104 | $19,440 | $187 |
| Viread | 12 | $15,168 | $1,264 |
| Ursodiol | 21 | $10,195 | $485 |
| Sirolimus | 32 | $9,475 | $296 |
| Tacrolimus | 55 | $6,885 | $125 |
| Cyclosporine Modified | 27 | $4,159 | $154 |
| Mycophenolate Mofetil | 59 | $4,011 | $68 |
| Tenofovir Disoproxil | 19 | $3,370 | $177 |
| Pantoprazole | 40 | $459 | $11 |
| Spironolactone | 39 | $408 | $10 |
| Fludrocortisone Acetate | 15 | $346 | $23 |
| Quetiapine | 12 | $235 | $20 |
| Amlodipine Besylate | 28 | $228 | $8 |
| Atorvastatin | 11 | $156 | $14 |
| Furosemide | 28 | $136 | $5 |
| Glipizide | 16 | $117 | $7 |
| Omeprazole | 16 | $103 | $6 |
| Losartan | 24 | $80 | $3 |
| Metoprolol | 13 | $44 | $3 |
2018: 32 drugs
| Nexavar | 14 | $134,015 | $9,572 |
| Xifaxan | 41 | $89,323 | $2,179 |
| Vemlidy | 70 | $89,206 | $1,274 |
| Entecavir | 128 | $78,338 | $612 |
| Baraclude | 29 | $39,983 | $1,379 |
| Viread | 16 | $21,280 | $1,330 |
| Ursodiol | 51 | $14,732 | $289 |
| Sirolimus | 42 | $11,667 | $278 |
| Mycophenolate Mofetil | 58 | $7,516 | $130 |
| Tacrolimus | 54 | $4,564 | $85 |
| Cyclosporine Modified | 25 | $3,849 | $154 |
| Ultra-Fine Nano Pen Needle | 20 | $1,399 | $70 |
| Generlac | 18 | $1,028 | $57 |
| Lactulose | 30 | $900 | $30 |
| Pantoprazole | 50 | $596 | $12 |
| Spironolactone | 35 | $542 | $15 |
| Potassium Chloride | 11 | $419 | $38 |
| Glipizide Er | 11 | $271 | $25 |
| Omeprazole | 50 | $240 | $5 |
| Nifedipine Er | 11 | $213 | $19 |
| Atorvastatin | 11 | $175 | $16 |
| Furosemide | 32 | $136 | $4 |
| Acyclovir | 13 | $124 | $10 |
| Ciprofloxacin | 11 | $123 | $11 |
| Quetiapine | 13 | $104 | $8 |
| Polyethylene Glycol 3350 | 14 | $91 | $6 |
| Amlodipine Besylate | 22 | $83 | $4 |
| Famotidine | 12 | $79 | $7 |
| Lisinopril | 12 | $79 | $7 |
| Metoprolol | 25 | $64 | $3 |
| Triamcinolone Acetonide | 11 | $55 | $5 |
| Simvastatin | 20 | $49 | $2 |
2017: 37 drugs
| Epclusa | 31 | $783,903 | $25,287 |
| Harvoni | 12 | $388,852 | $32,404 |
| Nexavar | 28 | $275,169 | $9,827 |
| Xifaxan | 65 | $132,673 | $2,041 |
| Viread | 79 | $95,770 | $1,212 |
| Entecavir | 111 | $80,926 | $729 |
| Procrit | 16 | $57,828 | $3,614 |
| Baraclude | 36 | $51,994 | $1,444 |
| Vemlidy | 35 | $35,785 | $1,022 |
| Ursodiol | 54 | $20,724 | $384 |
| Sirolimus | 38 | $11,010 | $290 |
| Mycophenolate Mofetil | 73 | $6,659 | $91 |
| Tacrolimus | 61 | $6,380 | $105 |
| Nexium | 22 | $5,636 | $256 |
| Cyclosporine Modified | 24 | $3,507 | $146 |
| Lactulose | 42 | $1,764 | $42 |
| Ribasphere | 17 | $1,251 | $74 |
| Pantoprazole | 55 | $819 | $15 |
| Ultra-Fine Nano Pen Needle | 14 | $737 | $53 |
| Zonisamide | 11 | $505 | $46 |
| Spironolactone | 29 | $381 | $13 |
| Azathioprine | 15 | $276 | $18 |
| Omeprazole | 49 | $269 | $5 |
| Nifedipine Er | 11 | $252 | $23 |
| Furosemide | 41 | $251 | $6 |
| Megestrol Acetate | 14 | $236 | $17 |
| Metoprolol | 28 | $212 | $8 |
| Amlodipine Besylate | 34 | $166 | $5 |
| Hydralazine | 13 | $146 | $11 |
| Clonidine | 18 | $127 | $7 |
| Acyclovir | 12 | $121 | $10 |
| Lisinopril | 17 | $121 | $7 |
| Carvedilol | 17 | $120 | $7 |
| Famotidine | 17 | $96 | $6 |
| Quetiapine | 12 | $87 | $7 |
| Ciprofloxacin | 11 | $67 | $6 |
| Simvastatin | 20 | $44 | $2 |
2016: 32 drugs
| Harvoni | 29 | $924,127 | $31,866 |
| Sovaldi | 16 | $436,372 | $27,273 |
| Epclusa | 15 | $373,685 | $24,912 |
| Nexavar | 28 | $281,969 | $10,070 |
| Daklinza | 12 | $252,092 | $21,008 |
| Entecavir | 165 | $151,999 | $921 |
| Xifaxan | 77 | $143,765 | $1,867 |
| Viread | 92 | $102,112 | $1,110 |
| Baraclude | 34 | $43,638 | $1,283 |
| Ursodiol | 71 | $24,284 | $342 |
| Nexium | 66 | $22,496 | $341 |
| Tacrolimus | 101 | $12,621 | $125 |
| Sirolimus | 25 | $10,273 | $411 |
| Ribavirin | 12 | $5,511 | $459 |
| Mycophenolate Mofetil | 69 | $4,013 | $58 |
| Cyclosporine Modified | 18 | $2,780 | $154 |
| Lactulose | 46 | $2,059 | $45 |
| Pantoprazole | 44 | $818 | $19 |
| Bd Ultra-Fine Pen Needle | 11 | $537 | $49 |
| Potassium Chloride | 19 | $493 | $26 |
| Megestrol Acetate | 28 | $463 | $17 |
| Omeprazole | 65 | $306 | $5 |
| Amlodipine Besylate | 62 | $255 | $4 |
| Metoprolol | 31 | $198 | $6 |
| Furosemide | 49 | $179 | $4 |
| Nifedipine Er | 15 | $172 | $11 |
| Hydralazine | 13 | $151 | $12 |
| Clonidine | 15 | $88 | $6 |
| Lisinopril | 16 | $74 | $5 |
| Ranitidine | 14 | $58 | $4 |
| Simvastatin | 17 | $40 | $2 |
| Atenolol | 13 | $17 | $1 |
2015: 33 drugs
| Harvoni | 38 | $1,204,127 | $31,688 |
| Sovaldi | 20 | $563,282 | $28,164 |
| Nexavar | 23 | $266,336 | $11,580 |
| Baraclude | 105 | $139,481 | $1,328 |
| Xifaxan | 76 | $138,251 | $1,819 |
| Viread | 88 | $83,241 | $946 |
| Entecavir | 81 | $78,149 | $965 |
| Ursodiol | 73 | $29,048 | $398 |
| Nexium | 62 | $23,243 | $375 |
| Prograf | 28 | $17,442 | $623 |
| Tacrolimus | 101 | $12,740 | $126 |
| Sirolimus | 14 | $8,813 | $630 |
| Epivir Hbv | 11 | $5,857 | $532 |
| Mycophenolate Mofetil | 59 | $3,451 | $58 |
| Ribasphere | 16 | $2,049 | $128 |
| Lactulose | 66 | $1,840 | $28 |
| Pantoprazole | 34 | $950 | $28 |
| Spironolactone | 45 | $637 | $14 |
| Fludrocortisone Acetate | 43 | $619 | $14 |
| Omeprazole | 83 | $566 | $7 |
| Megestrol Acetate | 25 | $506 | $20 |
| Furosemide | 74 | $355 | $5 |
| Generlac | 13 | $299 | $23 |
| Metoprolol | 29 | $278 | $10 |
| Amlodipine Besylate | 57 | $241 | $4 |
| Oxycodone | 14 | $179 | $13 |
| Nifedipine Er | 12 | $165 | $14 |
| Losartan | 19 | $120 | $6 |
| Prednisone | 12 | $94 | $8 |
| Ranitidine | 12 | $71 | $6 |
| Lisinopril | 16 | $49 | $3 |
| Simvastatin | 12 | $26 | $2 |
| Atenolol | 11 | $18 | $2 |
2014: 30 drugs
| Sovaldi | 56 | $1,781,860 | $31,819 |
| Olysio | 22 | $536,860 | $24,403 |
| Nexavar | 23 | $251,905 | $10,952 |
| Baraclude | 117 | $151,881 | $1,298 |
| Xifaxan | 65 | $97,289 | $1,497 |
| Viread | 73 | $65,377 | $896 |
| Tacrolimus | 76 | $21,459 | $282 |
| Nexium | 65 | $21,413 | $329 |
| Ribapak | 11 | $13,938 | $1,267 |
| Ursodiol | 52 | $9,976 | $192 |
| Prograf | 18 | $9,767 | $543 |
| Rapamune | 12 | $8,625 | $719 |
| Mycophenolate Mofetil | 76 | $5,375 | $71 |
| Ribavirin | 12 | $2,815 | $235 |
| Spironolactone | 57 | $1,592 | $28 |
| Ribasphere | 11 | $1,175 | $107 |
| Lactulose | 30 | $927 | $31 |
| Megestrol Acetate | 35 | $724 | $21 |
| Pantoprazole | 34 | $557 | $16 |
| Omeprazole | 54 | $549 | $10 |
| Furosemide | 85 | $376 | $4 |
| Fludrocortisone Acetate | 18 | $347 | $19 |
| Metoprolol | 17 | $307 | $18 |
| Amlodipine Besylate | 66 | $301 | $5 |
| Generlac | 12 | $300 | $25 |
| Azathioprine | 12 | $295 | $25 |
| Nifedipine Er | 11 | $155 | $14 |
| Sulfamethoxazole-Trimethoprim | 21 | $109 | $5 |
| Citalopram Hbr | 12 | $97 | $8 |
| Ranitidine | 12 | $73 | $6 |
2013: 24 drugs
| Nexavar | 29 | $283,280 | $9,768 |
| Baraclude | 123 | $136,418 | $1,109 |
| Xifaxan | 63 | $78,657 | $1,249 |
| Viread | 51 | $43,734 | $858 |
| Pegasys | 11 | $31,725 | $2,884 |
| Tacrolimus | 40 | $16,601 | $415 |
| Nexium | 37 | $11,184 | $302 |
| Mycophenolate Mofetil | 33 | $3,676 | $111 |
| Ursodiol | 42 | $2,628 | $63 |
| Lactulose | 37 | $1,828 | $49 |
| Spironolactone | 37 | $1,048 | $28 |
| Pantoprazole | 15 | $692 | $46 |
| Megestrol Acetate | 24 | $563 | $23 |
| Amlodipine Besylate | 75 | $464 | $6 |
| Potassium Chloride | 15 | $422 | $28 |
| Omeprazole | 40 | $379 | $9 |
| Furosemide | 82 | $343 | $4 |
| Metoprolol | 13 | $298 | $23 |
| Citalopram Hbr | 16 | $178 | $11 |
| Famotidine | 13 | $124 | $10 |
| Clonidine | 12 | $99 | $8 |
| Temazepam | 12 | $89 | $7 |
| Zolpidem | 13 | $59 | $5 |
| Prednisone | 11 | $33 | $3 |
Money from drug and device companies
$125 in 2025
| 2025 | 1 | 1 | None | $125 |
| 2022 | 2 | 16 | $30,650 | $31,910 |
| 2021 | 4 | 4 | $5,882 | $5,914 |
| 2020 | 3 | 4 | $9,606 | $9,626 |
| 2019 | 1 | 2 | $2,450 | $2,520 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | None | $125 | 1 payment
|
See the published payment
| GlaxoSmithKline | Meals · 2025-11-06 | None | $125 |
See earlier years (2022, 2021, 2020, 2019)
2022: $31,910
| GlaxoSmithKline | None | $28,150 | 4 payments
|
| Exelixis | Cabometyx | $3,760 | 12 payments
|
2021: $5,914
| Gilead Sciences | None | $2,710 | 1 payment
|
| Intercept Pharmaceuticals | None | $2,538 | 1 payment
|
| Janssen Scientific Affairs | None | $634 | 1 payment
|
| Novo Nordisk | None | $32 | 1 payment
|
2020: $9,626
| Intercept Pharmaceuticals | None | $8,881 | 2 payments
|
| Eli Lilly and | None | $725 | 1 payment
|
| Amgen | Evenity | $19 | 1 payment
|
2019: $2,520
| Gilead Sciences | None | $2,520 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2019 | Their institution | $1,128,624 |
| Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2019 | Their institution | $803,693 |
| Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2020 | Their institution | $486,887 |
| Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2020 | Their institution | $219,876 |
| Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2022 | Their institution | $203,000 |
| Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients Switched To Taf From Entecavir (Etv) · 2020 | Their institution | $182,000 |
| GlaxoSmithKline, LLC. · Phase 3 Multicenter, Randomized, Double-Blind, Study To Assess the Eff · 2024 | Their institution | $147,485 |
| Gilead Sciences, Inc. · Real-World Analysis of Hbv Data · 2019 | Their institution | $128,670 |
| Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2022 | Their institution | $120,664 |
| Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients Switched To Taf From Entecavir (Etv) · 2019 | Their institution | $96,978 |
| PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2021 | Their institution | $71,704 |
| Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2021 | Their institution | $70,000 |
| Gilead Sciences, Inc. · Hepatitis C Research Consortium (Hcrc) · 2020 | Their institution | $70,000 |
| PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2022 | Their institution | $68,903 |
| AstraZeneca Pharmaceuticals LP · Cosmos - A Phase Iia Randomized Double-Blind Placebo-Controlled Study To Evaluate the Safety Tolerability and Pharmacodynamics of Azd4831 in Participants With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) With Fibrosis · 2023 | Their institution | $50,269 |
| Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2023 | Their institution | $50,000 |
| Gilead Sciences, Inc. · Real World Analysis of Hbv Data · 2020 | Their institution | $47,760 |
| PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2024 | Their institution | $31,876 |
| GlaxoSmithKline, LLC. · Phase 3 Multicenter, Randomized, Double-Blind, Study To Assess the Eff · 2025 | Their institution | $18,864 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2019 | Their institution | $14,449 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2020 | Their institution | $13,413 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Efficacy and Safety of Tenofovir Alafenamide (Taf) Versus Tenofovir Disoproxil Fumarate (Tdf) in Virologically Suppressed Subjects With Chronic Hbv · 2019 | Their institution | $10,890 |
| AstraZeneca Pharmaceuticals LP · Cosmos - A Phase Iia Randomized Double-Blind Placebo-Controlled Study To Evaluate the Safety Tolerability and Pharmacodynamics of Azd4831 in Participants With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) With Fibrosis · 2024 | Their institution | $10,705 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2019 | Their institution | $8,807 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2021 | Their institution | $8,357 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2020 | Their institution | $6,902 |
| Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2024 | Their institution | $6,800 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2021 | Their institution | $6,615 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2022 | Their institution | $6,000 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study To Evaluate the Safety and Efficacy of Gs-9620 in Combination With Tenofovir Disoproxil Fumarate (Tdf) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment · 2019 | Their institution | $5,281 |
| PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2023 | Their institution | $4,974 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2022 | Their institution | $4,292 |
| PFIZER INC. · A Phase 2a Randomized Doubleblind Placebocontrolled Doseranging Parallel Group Study To Evaluate Safety Tolerability and Pharmacodynamics of Pf05221304 Administered Daily for 16weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease · 2019 | Their institution | $2,193 |
| Gilead Sciences, Inc. · A Phase 2, Open-Label Study To Evaluate the Safety and Efficacy of Switching To Tenofovir Alafenamide (Taf) From Tenofovir Disoproxil Fumarate (Tdf) and/Or Other Oral Antiviral Treatment (Oav) in Virologically Suppressed Chronic Hepatitis B Subjects With Renal and/Or Hepatic Impairment · 2019 | Their institution | $1,000 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1164558326
- Licence
- CA G79013California G79013: Current · expires 2027-10-31
- Trained
- University of California, San Diego School of Medicine, 1992
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G790130
- Taxonomy
- Federal specialty code 207RT0003X (207RT0003X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RI0008X (207RI0008X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-24
- NPI last updated
- 2025-02-26
- NPI record certified
- 2025-02-26
This is when the NPI record was last certified, not a medical board exam.